The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies
V Hoyos, I Borrello - Blood, The Journal of the American Society …, 2016 - ashpublications.org
V Hoyos, I Borrello
Blood, The Journal of the American Society of Hematology, 2016•ashpublications.orgThe treatment of multiple myeloma has evolved significantly over the last decades from
primarily alkylator-based chemotherapeutic agents with minimal efficacy to the introduction
of more effective agents including immune modulators and proteasome inhibitors, which
have changed the landscape of therapy for this disease. We are now entering a new era that
will increasingly integrate immunotherapy into standard treatment. This review discusses the
current immune-based strategies currently approved, as well as various immune …
primarily alkylator-based chemotherapeutic agents with minimal efficacy to the introduction
of more effective agents including immune modulators and proteasome inhibitors, which
have changed the landscape of therapy for this disease. We are now entering a new era that
will increasingly integrate immunotherapy into standard treatment. This review discusses the
current immune-based strategies currently approved, as well as various immune …
Abstract
The treatment of multiple myeloma has evolved significantly over the last decades from primarily alkylator-based chemotherapeutic agents with minimal efficacy to the introduction of more effective agents including immune modulators and proteasome inhibitors, which have changed the landscape of therapy for this disease. We are now entering a new era that will increasingly integrate immunotherapy into standard treatment. This review discusses the current immune-based strategies currently approved, as well as various immune approaches being actively investigated including monoclonal antibodies, checkpoint inhibitors, vaccines, and adoptive T-cell therapies.
ashpublications.org